International Journal of Endocrinology and Metabolism

Published by: Kowsar

Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study

Azra Ramezankhani 1 , Hadi Harati 1 , Mohammadreza Bozorgmanesh 1 , Maryam Tohidi 1 , Davood Khalili 1 , 2 , Fereidoun Azizi 1 , 3 and Farzad Hadaegh 1 , *
Authors Information
1 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Department of Biostatistics and Epidemiology, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84784
  • Published Online: October 16, 2018
  • Article Type: Review Article
  • Received: September 1, 2018
  • Revised: October 2, 2018
  • Accepted: October 7, 2018
  • DOI: 10.5812/ijem.84784

To Cite: Ramezankhani A, Harati H , Bozorgmanesh M , Tohidi M , Khalili D , et al. Diabetes Mellitus: Findings from 20 Years of the Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84784. doi: 10.5812/ijem.84784.

Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137-49. doi: 10.1016/j.diabres.2013.11.002. [PubMed: 24630390].
  • 2. Federation I. IDF diabetes atlas. 6th ed. 2015.
  • 3. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373(18):1720-32. doi: 10.1056/NEJMoa1504347. [PubMed: 26510021].
  • 4. World Health Organization. The top 10 causes of death. 2018. Available from:
  • 5. Majeed A, El-Sayed AA, Khoja T, Alshamsan R, Millett C, Rawaf S. Diabetes in the Middle-East and North Africa: An update. Diabetes Res Clin Pract. 2014;103(2):218-22. doi: 10.1016/j.diabres.2013.11.008. [PubMed: 24300017].
  • 6. Zabetian A, Kelli HM, Echouffo-Tcheugui JB, Narayan KM, Ali MK. Diabetes in the Middle East and North Africa. Diabetes Res Clin Pract. 2013;101(2):106-22. doi: 10.1016/j.diabres.2013.03.010. [PubMed: 23642969].
  • 7. Amini M, Afshin-Nia F, Bashardoost N, Aminorroaya A, Shahparian M, Kazemi M. Prevalence and risk factors of diabetes mellitus in the Isfahan city population (aged 40 or over) in 1993. Diabet Res Clinica Pract. 1997;38(3):185-90. doi: 10.1016/s0168-8227(97)00099-5.
  • 8. Larijani B, Abolhasani F, Mohajeri-Tehrani MR, Tabtabaie O. [Prevalence of diabetes mellitus in Iran in 2000]. Iranian J Diabet Metabol. 2005;4(3):75-83. Persian.
  • 9. Esteghamati A, Gouya MM, Abbasi M, Delavari A, Alikhani S, Alaedini F, et al. Prevalence of diabetes and impaired fasting glucose in the adult population of Iran: National survey of risk factors for non-communicable diseases of Iran. Diabet Care. 2008;31(1):96-8. doi: 10.2337/dc07-0959. [PubMed: 17921357].
  • 10. Azizi F, Madjid M, Rahmani M, Emami H, Mirmiran PA, Hadjipour R. [Tehran Lipid and Glucose Study (TLGS): Rationale and design]. Iranian J Endocrinol Metabol. 2000;2(2):77-86. Persian.
  • 11. Mirbolouk M, Derakhshan A, Charkhchi P, Guity K, Azizi F, Hadaegh F. [Incidence and predictors of early adulthood pre‐diabetes/type 2 diabetes, among Iranian adolescents: The Tehran lipid and glucose study]. Diabet Care. 2016;17(8):608-16. Persian.
  • 12. Hadaegh F, Bozorgmanesh MR, Ghasemi A, Harati H, Saadat N, Azizi F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran lipid and glucose study. BMC Public Health. 2008;8:176. doi: 10.1186/1471-2458-8-176. [PubMed: 18501007]. [PubMed Central: PMC2413226].
  • 13. Derakhshan A, Sardarinia M, Khalili D, Momenan AA, Azizi F, Hadaegh F. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran lipid and glucose study. PLoS One. 2014;9(7). e102563. doi: 10.1371/journal.pone.0102563. [PubMed: 25029368]. [PubMed Central: PMC4100911].
  • 14. Hadaegh F, Derakhshan A, Zafari N, Khalili D, Mirbolouk M, Saadat N, et al. Pre-diabetes tsunami: Incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. Diabet Med. 2017;34(1):69-78. doi: 10.1111/dme.13034. [PubMed: 26606421].
  • 15. Harati H, Hadaegh F, Saadat N, Azizi F. Population-based incidence of Type 2 diabetes and its associated risk factors: Results from a six-year cohort study in Iran. BMC Public Health. 2009;9(1):186. doi: 10.1186/1471-2458-9-186. [PubMed: 19531260]. [PubMed Central: PMC2708154].
  • 16. Derakhshan A, Tohidi M, Arshi B, Khalili D, Azizi F, Hadaegh F. Relationship of hyperinsulinaemia, insulin resistance and beta-cell dysfunction with incident diabetes and pre-diabetes: The Tehran lipid and glucose study. Diabet Med. 2015;32(1):24-32. doi: 10.1111/dme.12560. [PubMed: 25131451].
  • 17. Tohidi M, Bozorgmanesh M, Mohebi R, Khalili D, Saadat N, Khorrami N, et al. Non-linear association between 25-hydroxyvitamin D and the incidence of type 2 diabetes: A community-based nested case-control study. Diabet Med. 2013;30(8):934-8. doi: 10.1111/dme.12180. [PubMed: 23560705].
  • 18. Tohidi M, Harati H, Hadaegh F, Mehrabi Y, Azizi F. Association of liver enzymes with incident type 2 diabetes: A nested case control study in an Iranian population. BMC Endocr Disord. 2008;8(1):5. doi: 10.1186/1472-6823-8-5. [PubMed: 18533046]. [PubMed Central: PMC2438361].
  • 19. Jahangiri Noudeh Y, Hadaegh F, Vatankhah N, Momenan AA, Saadat N, Khalili D, et al. Wrist circumference as a novel predictor of diabetes and prediabetes: Results of cross-sectional and 8.8-year follow-up studies. J Clin Endocrinol Metab. 2013;98(2):777-84. doi: 10.1210/jc.2012-2416. [PubMed: 23341488].
  • 20. Ramezankhani A, Hadavandi E, Pournik O, Shahrabi J, Azizi F, Hadaegh F. Decision tree-based modelling for identification of potential interactions between type 2 diabetes risk factors: A decade follow-up in a Middle East prospective cohort study. BMJ Open. 2016;6(12). e013336. doi: 10.1136/bmjopen-2016-013336. [PubMed: 27909038]. [PubMed Central: PMC5168628].
  • 21. Ramezankhani A, Pournik O, Shahrabi J, Khalili D, Azizi F, Hadaegh F. Applying decision tree for identification of a low risk population for type 2 diabetes. Tehran lipid and glucose study. Diabet Res Clin Pract. 2014;105(3):391-8. doi: 10.1016/j.diabres.2014.07.003. [PubMed: 25085758].
  • 22. Ramezankhani A, Azizi F, Hadaegh F, Momenan AA. Diabetes and number of years of life lost with and without cardiovascular disease: A multi-state homogeneous semi-Markov model. Acta Diabetologica. 2018;55(3):253-62. doi: 10.1007/s00592-017-1083-x.
  • 23. Sardarinia M, Akbarpour S, Lotfaliany M, Bagherzadeh-Khiabani F, Bozorgmanesh M, Sheikholeslami F, et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a Middle Eastern population over a decade follow-up: Tehran lipid and glucose study. PLoS One. 2016;11(12). e0167623. doi: 10.1371/journal.pone.0167623. [PubMed: 27930696]. [PubMed Central: PMC5145170].
  • 24. Khalili D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: A 10-year population-based cohort study. PLoS One. 2014;9(8). e105804. doi: 10.1371/journal.pone.0105804. [PubMed: 25162590]. [PubMed Central: PMC4146560].
  • 25. Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: Results from 7.6 year follow up in a Middle East population. Cardiovasc Diabetol. 2010;9(1):84. doi: 10.1186/1475-2840-9-84. [PubMed: 21129219]. [PubMed Central: PMC3016329].
  • 26. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. BMC Neurol. 2012;12(1):117. doi: 10.1186/1471-2377-12-117. [PubMed: 23031547]. [PubMed Central: PMC3517457].
  • 27. Bozorgmanesh M, Hadaegh F, Sheikholeslami F, Azizi F. Cardiovascular risk and all-cause mortality attributable to diabetes: Tehran lipid and glucose study. J Endocrinol Invest. 2012;35(1):14-20. doi: 10.3275/7728. [PubMed: 21586894].
  • 28. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, Khalili D, et al. Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran lipid and glucose study. Diabet Metab Res Rev. 2016;32(6):596-606. doi: 10.1002/dmrr.2776. [PubMed: 26787367].
  • 29. Bozorgmanesh M, Hadaegh F, Ghaffari S, Harati H, Azizi F. A simple risk score effectively predicted type 2 diabetes in Iranian adult population: Population-based cohort study. Eur J Public Health. 2011;21(5):554-9. doi: 10.1093/eurpub/ckq074. [PubMed: 20534689].
  • 30. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38(6):628-36. doi: 10.1016/j.amepre.2010.03.003. [PubMed: 20494239].
  • 31. Sarraf-Zadegan N, Sadri G, Malek Afzali H, Baghaei M, Mohammadi Fard N, Shahrokhi S, et al. Isfahan healthy heart programme: A comprehensive integrated community-based programme for cardiovascular disease prevention and control. Design, methods and initial experience. Acta Cardiol. 2003;58(4):309-20. doi: 10.2143/AC.58.4.2005288. [PubMed: 12948036].
  • 32. Najafipour H, Mirzazadeh A, Haghdoost A, Shadkam M, Afshari M, Moazenzadeh M, et al. Coronary artery disease risk factors in an Urban and Peri-urban setting, Kerman, Southeastern Iran (KERCADR Study): Methodology and preliminary report. Iran J Public Health. 2012;41(9):86-92. [PubMed: 23193513]. [PubMed Central: PMC3494222].
  • 33. Ziaee A, Esmailzadehha N, Ghorbani A, Asefzadeh S. Association between uric acid and metabolic syndrome in Qazvin metabolic diseases study (QMDS), Iran. Glob J Health Sci. 2013;5(1):155-65. doi: 10.5539/gjhs.v5n1p155. [PubMed: 23283048].
  • 34. Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar AA, Hekmatdoost A, et al. Prospective epidemiological research studies in Iran (the PERSIAN Cohort Study): Rationale, objectives, and design. Am J Epidemiol. 2018;187(4):647-55. doi: 10.1093/aje/kwx314. [PubMed: 29145581].
  • 35. ICC. Iran Cohort Consortium (ICC). 2018. Available from:
  • 36. Goldstein LB, Bushnell CD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42(2):517-84. doi: 10.1161/STR.0b013e3181fcb238. [PubMed: 21127304].
  • 37. Daneshpour MS, Fallah MS, Sedaghati-Khayat B, Guity K, Khalili D, Hedayati M, et al. Rationale and design of a genetic study on cardiometabolic risk factors: Protocol for the Tehran cardiometabolic genetic study (TCGS). JMIR Res Protoc. 2017;6(2). e28. doi: 10.2196/resprot.6050. [PubMed: 28232301]. [PubMed Central: PMC5344981].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments